Dosing JAK Inhibitors in Patients With Myelofibrosis

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

CML Alliance
Enable registration in settings - general
Compare items
  • Total (0)
Shopping cart